Brian F Kiesel1,2, Joshua J Deppas1,2, Jianxia Guo1, Robert A Parise1, David A Clump3, Christopher J Bakkenist3,4, Jan H Beumer5,6,7. 1. Cancer Therapeutics Program, UPMC Hillman Cancer Center, Room G27e, 5117 Centre Ave, Pittsburgh, PA, 15213, USA. 2. Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA. 3. Department of Radiation Oncology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. 4. Department of Pharmacology and Chemical Biology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. 5. Cancer Therapeutics Program, UPMC Hillman Cancer Center, Room G27e, 5117 Centre Ave, Pittsburgh, PA, 15213, USA. beumerj@gmail.com. 6. Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA. beumerj@gmail.com. 7. Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. beumerj@gmail.com.
Abstract
PURPOSE: Ataxia Telangiectasia and Rad3-related (ATR) is a pivotal component of the DNA damage response and repair pathways that is activated in responses to cytotoxic cancer treatments. Several ATR inhibitors (ATRi) are in development that block the ATR mediated DNA repair and enhance the damage associated with cytotoxic therapy. BAY-1895344 (elimusertib) is an orally available ATRi with preclinical efficacy that is in clinical development. Little is known about the pharmacokinetics (PK) which is of interest, because tissue exposure and ATR inhibition may relate to toxicities or responses. METHODS: To evaluate BAY-1895344 PK, a sensitive LC-MS/MS method was utilized for quantitation in mouse plasma and tissues. PK studies in mice were first conducted to determine dose linearity. In vivo metabolites were identified and analyzed semi-quantitatively. A compartmental PK model was developed to describe PK behavior. An extensive PK study was then conducted in tumor-bearing mice to quantitate tissue distribution for relevant tissues. RESULTS: Dose linearity was observed from 1 to 10 mg/kg PO, while at 40 mg/kg PO bioavailability increased approximately fourfold due to saturation of first-pass metabolism, as suggested by metabolite analyses and a developed compartmental model. Longer half-lives in PO treated mice compared to IV treated mice indicated absorption-rate limited elimination. Tissue distribution varied but showed extensive distribution to bone marrow, brain, and spinal cord. CONCLUSIONS: Complex PK behavior was limited to absorption processes which may not be recapitulated clinically. Tissue partition coefficients may be used to contrast ATR inhibitors with respect to their efficacy and toxicity.
PURPOSE: Ataxia Telangiectasia and Rad3-related (ATR) is a pivotal component of the DNA damage response and repair pathways that is activated in responses to cytotoxic cancer treatments. Several ATR inhibitors (ATRi) are in development that block the ATR mediated DNA repair and enhance the damage associated with cytotoxic therapy. BAY-1895344 (elimusertib) is an orally available ATRi with preclinical efficacy that is in clinical development. Little is known about the pharmacokinetics (PK) which is of interest, because tissue exposure and ATR inhibition may relate to toxicities or responses. METHODS: To evaluate BAY-1895344 PK, a sensitive LC-MS/MS method was utilized for quantitation in mouse plasma and tissues. PK studies in mice were first conducted to determine dose linearity. In vivo metabolites were identified and analyzed semi-quantitatively. A compartmental PK model was developed to describe PK behavior. An extensive PK study was then conducted in tumor-bearing mice to quantitate tissue distribution for relevant tissues. RESULTS: Dose linearity was observed from 1 to 10 mg/kg PO, while at 40 mg/kg PO bioavailability increased approximately fourfold due to saturation of first-pass metabolism, as suggested by metabolite analyses and a developed compartmental model. Longer half-lives in PO treated mice compared to IV treated mice indicated absorption-rate limited elimination. Tissue distribution varied but showed extensive distribution to bone marrow, brain, and spinal cord. CONCLUSIONS: Complex PK behavior was limited to absorption processes which may not be recapitulated clinically. Tissue partition coefficients may be used to contrast ATR inhibitors with respect to their efficacy and toxicity.
Authors: Jan H Beumer; Robert A Parise; Beatriz Kanterewicz; Martin Petkovich; David Z D'Argenio; Pamela A Hershberger Journal: Steroids Date: 2012-01-20 Impact factor: 2.668
Authors: Frank P Vendetti; Pooja Karukonda; David A Clump; Troy Teo; Ronald Lalonde; Katriana Nugent; Matthew Ballew; Brian F Kiesel; Jan H Beumer; Saumendra N Sarkar; Thomas P Conrads; Mark J O'Connor; Robert L Ferris; Phuoc T Tran; Greg M Delgoffe; Christopher J Bakkenist Journal: J Clin Invest Date: 2018-08-13 Impact factor: 14.808
Authors: Antje M Wengner; Gerhard Siemeister; Ulrich Lücking; Julien Lefranc; Lars Wortmann; Philip Lienau; Benjamin Bader; Ulf Bömer; Dieter Moosmayer; Uwe Eberspächer; Sven Golfier; Christoph A Schatz; Simon J Baumgart; Bernard Haendler; Pascale Lejeune; Andreas Schlicker; Franz von Nussbaum; Michael Brands; Karl Ziegelbauer; Dominik Mumberg Journal: Mol Cancer Ther Date: 2019-10-03 Impact factor: 6.261
Authors: Timothy A Yap; David S P Tan; Angelika Terbuch; Reece Caldwell; Christina Guo; Boon Cher Goh; Valerie Heong; Noor R Md Haris; Saira Bashir; Yvette Drew; David S Hong; Funda Meric-Bernstam; Gary Wilkinson; Joseph Hreiki; Antje M Wengner; Friedhelm Bladt; Andreas Schlicker; Matthias Ludwig; Yinghui Zhou; Li Liu; Sonal Bordia; Ruth Plummer; Eleni Lagkadinou; Johann S de Bono Journal: Cancer Discov Date: 2020-09-28 Impact factor: 38.272